Net sales for Novartis grew by 8% in the full year, with core operating income up by 14%. In the fourth quarter, net sales saw a slight decrease of 1%, but core operating income increased by 1%. The company’s priority brands, including Kisqali, Kesimpta, and Cosentyx, continued to perform well. Novartis also announced an increase in dividend and guidance for 2026, expecting low single-digit growth in net sales and a decline in core operating income.

Novartis’ CEO, Vas Narasimhan, highlighted the company’s strong performance in 2025, with high single-digit sales growth and core margin expansion. Key growth drivers for Novartis include Kisqali, Kesimpta, and Pluvicto, which continued their strong trajectory. The company also advanced several potential multi-blockbusters in their pipeline, with FDA approvals and positive Phase III readouts across various treatments. Novartis expects to grow through the largest patent expiry in its history in 2026.

In terms of financials, Novartis saw an increase in operating income, net income, and core EPS for both the fourth quarter and full year. The company’s core operating income margin increased to 40.1% of net sales. Novartis also reported a free cash flow of USD 17.6 billion, driven by higher net cash flows from operating activities. The company also announced a proposed dividend of CHF 3.70 per share for 2025, representing a 5.7% increase from the previous year. Novartis is focused on accelerating growth, delivering returns, and strengthening its foundations through strategic deals and pipeline advancements.

Read more at GlobeNewswire: Novartis delivered high single-digit sales growth, achieved